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Abstract Trichosanthin (TCS) is a type I ribosome inactivat-
ing (RI) protein possessing anti-tumor and antiviral activity,
including human immunode¢ciency virus (HIV). The mechanism
of these actions is not entirely clear, but is generally attributed
to its RI property. In order to study the relationship between the
anti-HIV-1 activity of TCS and its RI activity, three TCS
mutants with di¡erent RI activities were constructed by using
site-directed mutagenesis. The anti-HIV-1 activities of the three
mutants were tested in vitro. Results showed that two TCS
mutants, namely TCSMð120123Þ, TCSE160A=E189A, with the great-
est decrease in RI activity, lost almost all of the anti-HIV
activity and cytopathic e¡ect. Another mutant TCSR122G, which
exhibited a 160-fold decrease in RI activity, retained some anti-
HIV activity. The results from this study suggested that RI
activity of TCS may have signi¢cant contribution to its anti-
HIV-1 property.
0 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Trichosanthin (TCS) is a type I ribosome inactivating pro-
tein (RIP) isolated from the root tubers of the Chinese medic-
inal herb Trichosanthes kirilowii Maxim (cucurbitaceae). Its
crude extracts have been used as an abortifacient agent for
centuries in China [1]. TCS possesses a wide spectrum of bio-
logical and pharmacological properties, including anti-tumor,
antiviral, immunosuppressive and abortifacient activity [2,3].
The ¢nding that TCS preferentially inhibited replication of
human immunode¢ciency virus type 1 (HIV-1) in both acutely
infected T-lymphoblastoid cells and chronically infected mac-
rophages in vitro generated some excitement [4]. Phase I/II
clinical trials with TCS alone or in combination with zidovu-
dine or dideoxinosine showed that TCS was able to decrease
the serum HIV-1 p24 antigen level and to increase the per-
centage of CD4þ cells in patients with acquired immunode¢-
ciency syndrome (AIDS) and AIDS-related complex [5]. In
addition to TCS, many other RIPs, including MAP30,
GAP31, DAP30, DAP32, TAP29, PAP, bryodin, MMC and
trichobitacin, have been reported to inhibit HIV-1 replication
in vitro [6^12].
The exact mechanism of these RIPs on anti-HIV activity
remains to be determined. It is generally believed that the
antiviral activity is related to the ribosome inactivating (RI)
activity. The argument against it is that not all RIPs have
antiviral activity. In this study, the relationship between RI
activity of TCS and its anti-HIV-1 activity was investigated.
TCS consists of 247 amino acid residues with no disul¢de
bond. Since the three-dimensional crystallographic structure
of TCS complex with its analog substrate has been elucidated,
the study of structure^function relationship in RI activity is
relatively clear. There are eight K-helices which are relatively
concentrated at the center of the molecule and surrounded by
13 L-strands. Two domains in structure of TCS had been
found: a larger N-terminal domain with approximately 160
residues and a smaller C-terminal domain possessing about 60
residues. Type I RIPs or the A chain of type II RIPs have
some homology in amino acid sequence, and have some con-
servative amino acid residues that may be involved in the
active site, for example in TCS, Tyr14, Arg22, Tyr70,
Tyr111, Arg122, Glu160, Ala161, Arg163, Glu189, Trp192
etc., most of which lie at the brink of the cleft formed by
the big and the small domain of TCS [1]. In order to study
this relationship of the RI activity of TCS and its anti-
HIV-1 activity, three TCS mutants namely TCSMð120123Þ,
TCSE160A=E189A and TCSR122G with di¡erent RI activities
were constructed by using site-directed mutagenesis. The
anti-HIV-1 activities were assayed in vitro to test for the re-
lationship.
2. Materials and methods
2.1. Reagents and chemicals
AZT (3P-azido-3P-deoxythymidine) was purchased from Sigma, and
horseradish peroxidase (HRP)-labeled goat anti-human IgG was pur-
chased from Sino-America Biotechnology Company. Monoclonal
antibody (McAb) to HIV-1 p24 and human polyclonal anti-HIV-1
serum were kindly donated by Dr. Hiroo Hoshino (Department of
Virology and Preventive Medicine, Gunma University School of Med-
icine, Japan).
2.2. Natural TCS (nTCS) and TCS mutants
nTCS was puri¢ed from the root tuber of T. kirilowii. Three TCS
mutated genes were constructed by polymerase chain reaction and the
mutants were expressed and puri¢ed as described previously [13,14].
2.3. Virus and cell lines
C8166 and H9 cells were obtained from Medical Research Council
(MRC), AIDS Reagent Project, and maintained in RPMI 1640 sup-
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plemented with 10% heat-inactivated fetal calf serum. HIV-1IIIB was
obtained from the culture supernatant of H9/HIV-1IIIB cells. The 50%
HIV-1 tissue culture infectious dose (TCID50) in C8166 cells was
determined and calculated by the Reed and Muench method. Virus
stocks were stored in small aliquots at 370‡C. The titer of virus stock
was 9U105 TCID50 per ml.
2.4. Assay for RI activity
The RI activity of nTCS and its mutants on protein synthesis was
measured in a rabbit reticulocyte lysate cell-free system, using an
intact rabbit reticulocyte lysate as a source of ribosome, mRNA
and other endogenous factors. Protein synthesis was assessed by
[3H]leucine incorporation [13]. The relative activity compared to
nTCS in IC50 values was obtained.
2.5. Cytotoxicity assay
The cellular toxicity of compounds on C8166 cells was assessed by
MTT colorimetric assay as described previously [15]. Brie£y, 100 Wl of
3U104 cells was seeded on a microtiter plate, 100 Wl of various con-
centrations of compounds was added and incubated at 37‡C in a
humidi¢ed atmosphere of 5% CO2 for 72 h. Discard 100 Wl super-
natant, MTT reagent was added and incubated for 4 h, 100 Wl 50%
DMF^10% SDS was added. After the formazum was dissolved com-
pletely, the plates were read on a Bio-Tek ELx 800 enzyme-linked
immunosorbent assay (ELISA) reader at 595 nm/630 nm. The results
were shown by absorbance values.
2.6. ELISA for HIV-1 p24 antigen
HIV-1 p24 antigen in a cell-free culture medium was measured
using an antigen capture ELISA as described previously [12]. Brie£y,
96-well microtiter plates coated with McAb to p24 antigen were
blocked by 5% skim milk powder, then detergent-treated cell-free cul-
ture medium was added, and incubated for 2 h at 37‡C. The plates
were then incubated with 1:500 diluted human polyclonal anti-HIV-1
sera, followed by incubation with HRP-labeled goat-anti human IgG
and OPD reaction solution was added to the wells. The optical density
of the plates was read on a Bio-Tek ELx 800 ELISA reader at 490 nm
with reference 630 nm within 30 min of stopping the reaction. The
inhibition (%) of p24 antigen expression was calculated. The concen-
tration of nTCS or mutants reducing p24 antigen expression by 50%
(EC50) was determined from the dose^response curve.
2.7. Anti-HIV activity assay
C8166 cells (3U105/ml) were pretreated with nTCS or mutants at
various concentrations at 37‡C for 1 h, and then were infected with
HIV-1IIIB at a multiplicity of infection (M.O.I.) of 0.015. They were
then cultured in the presence of either nTCS or mutants in a ¢nal
volume of 200 Wl. The plates were incubated in a humidi¢ed incubator
at 37‡C and 5% CO2. Each condition was performed in triplicate.
AZT was used for positive control. After 3 days of culture, the num-
ber of syncytia (multinucleated giant cells) in each well was counted
under an inverted microscope. The percentage inhibition of syncytial
cell formation was calculated by the percentage of syncytial cell num-
ber in compounds-treated culture to that in infected control culture.
Terminated cell culture was centrifuged and harvested, and cell-free
supernatant was used to measure the HIV-1 p24 antigen level with
antigen capture ELISA assay.
3. Results
3.1. Sequence of nTCS mutants and its comparison with nTCS
A comparison of the amino acid sequence between nTCS
and the three mutants is shown as Fig. 1. The Lys120-Ile121-
Arg122-Glu123 were replaced by Ser120-Ala121-Gly122-
Gly123 in TCSMð120123Þ. Both Glu160 and Glu189 were sub-
stituted by Ala in TCSE160A=E189A, and the Arg122 was re-
placed by Gly122 in TCSR122G.
3.2. RI activity of nTCS and its mutants
A rabbit reticulocyte lysate cell-free system was used to
measure the RI activity of nTCS and the mutants at di¡erent
concentrations in vitro. IC50 of nTCS active site mutants,
TCSMð120123Þ, TCSE160A=E189A and TCSR122G exhibited a
markedly decrease in RI activity. Their RI activities were
4000-, 1800- and 160-fold lower than that of nTCS, respec-
tively. This is consistent with the ¢nding of other investigators
[13,14].
3.3. Cytotoxicity of nTCS and its mutants on C8166 cells
The cytotoxicity of nTCS and its mutants on C8166 cells is
summarized in Fig. 2. At 10 Wg/ml, nTCS and TCSR122G
caused about 43.2Q 2.3% and 36.1Q 0.9% inhibition of cell
growth, respectively. TCSMð120123Þ and TCSE160A=E189A exhib-
ited signi¢cantly lower cytotoxic e¡ects than that of nTCS.
nTCS and mutants slightly a¡ected cell growth and cell via-
bility was over 80% at a concentration below 10 Wg/ml.
3.4. Anti-HIV-1 activity of nTCS and mutants
The virus-induced cytopathic e¡ect is quantitated by the
syncytium formation. The inhibition of syncytium formation
in a dose-dependent manner was observed in the presence of
nTCS, an EC50 of 0.38Q 0.09 Wg/ml was obtained. TCSR122G
exhibited lower e¡ects on inhibition of syncytium forma-
tion than that of nTCS. At 10 Wg/ml, TCSR122G caused
50.10Q 0.87% inhibition of syncytium formation (EC50 9.8 Q
2.3 Wg/ml). TCSMð120123Þ and TCSE160A=E189A lost their e¡ects
on inhibition of syncytium formation (Fig. 2A). Simul-
taneously, inhibition of HIV-1 p24 protein expression on
acutely infected cells by nTCS and its mutants was detected
to measure HIV-1 replication by an antigen capture ELISA
method. Like inhibition of syncytium formation, the inhibi-
tion of p24 antigen expression by nTCS was at a dose-depen-
dent manner with an EC50 of 0.32 Q 0.02 Wg/ml. All the mu-
tants exhibit a decrease in anti-HIV activity at the selected
concentration. TCSR122G exhibited 46.4Q 4.5% inhibition of
Fig. 1. Comparison of the amino acid sequence between nTCS and
mutants. The changes in amino acids are denoted by bold and italic.
‘3’, indicating the same amino acids compared to nTCS.
Fig. 2. Cytotoxicity of nTCS and its mutants on C8166 cells. The
cell viability was measured by MTT assay. Data are expressed as
meansQS.E.M. of triplicate measurements. **P6 0.01 versus nTCS.
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p24 antigen expression at 10 Wg/ml. TCSMð120123Þ and
TCSE160A=E189A lost the anti-HIV-1 activities, no inhibition
of p24 antigen expression was observed at these concentra-
tions (Fig. 3B).
4. Discussion
All RIPs with an anti-HIV property have RI activity, but
most of the RIPs with RI and/or abortifacient activities do
not possess anti-HIV activity [16]. Therefore, the direct rela-
tionship between RI activity and anti-HIV activity of the
RIPs remains to be examined. PAP RI activity is distinct
from anti-HIV activity [9], while MAP30 and related RIPs
inhibit HIV-1 at a concentration that showed little e¡ects
on ribosome function [6,17]. The potent antiviral activity of
PAP may in part be due to the unique ability of PAP to
extensively depurinate viral RNA, including HIV-1 RNA [18].
In order to study the relationship between RI activity
of TCS and its anti-HIV activity, three nTCS RI mutants
namely TCSMð120123Þ, TCSE160A=E189A and TCSR122G were
constructed.
The 120^123 (Lys-Ile-Arg-Glu) region lying at the entrance
of the cleft, is one of the four hydrophilic areas of the nTCS
molecule, and has the highest homology of amino acid se-
quence in several type I RIPs [13]. Crystallographic data dem-
onstrated that this region has strong interaction with other
side chains and the protein backbone by forming hydrogen
bonding [19]. The substitute mutant TCSMð120123Þ was
changed from Lys-Ile-Arg-Glu to Ser-Ala-Gly-Gly. This re-
placement maintained its peptide backbone, but lost most of
its interaction with other amino acids due to the change from
hydrophilic to hydrophobic properties, resulting in the 4000-
fold decrease of in vitro RI activity versus nTCS.
Since Arg122 is the most conservative amino acid, and is
related to ¢ve hydrogen bonds formation, therefore Arg122
may take on a key role for this region action [1]. The amino
acid substitution of Arg122 by Gly leads to a 160-fold de-
crease in RI activity. TCSR122G is now obtained as a single-
sited mutant which possesses the greatest e¡ect on nTCS RI
activity.
Both Glu160 and Glu189 lie at the placket area of the
nTCS RI activity site. The negative charges of Glu160 may
play a role in stabilizing the nTCS transition-state complex
which presumably possesses oxocarbonium characteristics.
Glu189 can partly substitute for Glu160 by furnishing a car-
boxylate group for its RI activity when Glu160 is lost [14].
When Glu160, Glu189, the polar residues with long side
chains, were replaced by Ala, the non-polar residues with
short side chains, the surplus room would be ¢lled with two
water molecules, which formed the hydrogen bonding, then
substituted partly the carboxylate group e¡ects of Glu160 and
Glu189 [20]. TCSE160A=E189A, both Glu160 and Glu189 were
replaced by Ala, its RI activity was 1800-fold lower than that
of nTCS.
Our results showed that along with the decrease in RI ac-
tivity, the anti-HIV-1 activity of nTCS was declined. When RI
activity was 160-fold downward (TCSR122G), the mutant still
reserved some anti-HIV activity, but when the RI activity
dropped 1800-fold (TCSE160A=E189A), the mutant lost almost
all of the anti-HIV activity, and so did the mutant
TCSMð120123Þ with the 4000-fold decrease in RI activity. Sup-
pression of HIV replication was partly due to inhibition of cell
proliferation and partly due to direct inhibition of HIV rep-
lication by TCS and its mutants. Fig. 3 showed that TCS
inhibited cell growth by 43.2% and reduced HIV-1 p24 anti-
gen expression by 78.2% at 10 Wg/ml. The di¡erence repre-
sented direct inhibition of HIV replication by TCS. At the
same concentration, TCSR122G inhibited cell growth by
36.1% and reduced HIV p24 antigen expression by 46.4%.
At 2 Wg/ml, TCS caused only 18% inhibition of host cells
growth, but it possessed signi¢cant anti-HIV activity with
65.3% inhibition of p24 production. These results demon-
strated that TCS mutant clearly exhibited reduction in anti-
HIV activity independent of its e¡ect on cell proliferation. So
we can conclude that nTCS anti-HIV-1 activity is related to
its RI activity. There is no reason to believe in the mutant
active site residues, which located in the active cleft, involved
in the membrane binding, endocytosis and translocation pro-
cess in cytosol.
Fig. 3. Anti-HIV activity of nTCS and its mutants. C8166 cells
were pretreated and infected with HIV-1IIIB at a M.O.I. of 0.015.
Syncytial formation inhibition was quanti¢ed under an inverted
microscope (A) and p24 antigen expression in supernatants was per-
formed by capture ELISA (B). Data are expressed as meansQ
S.E.M. of triplicate measurements (n=9). **P6 0.01, ***P6 0.001
versus nTCS.
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nTCS cannot inhibit expression of p24 antigen in chroni-
cally HIV-1-infected H9 cells. This suggested that disturbing
stages of nTCS were not virus maturity, infectivity and re-
lease, replication of viral genome. In addition, our data
showed that nTCS was unable to block fusion between the
chronically HIV-1IIIB-infected H9 cells and uninfected C8166
cells in coculture (data not shown). This result suggested that
nTCS did not interfere with the absorption and binding be-
tween host cells and viruses. RIPs were reported to possess
topological inactivation activity which was also proposed to
be important for their antiviral action [21,22], and MAP30,
GAP31 and TCS were found to be inhibitors of HIV-1 inte-
grase [23,24].
From this study we can conclude that TCS RI activity
contributes to its anti-HIV activity, but the relationship
should not be simple and direct, there should be other path-
ways involved in the e¡ect of TCS anti-HIV.
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